Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

9MW 0211

Next Previous
Drug Profile

9MW 0211

Alternative Names: 9MW-0211; MW-02

Latest Information Update: 04 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Apexigen; Mabwell (Shanghai) Bioscience
  • Developer Mabwell (Shanghai) Bioscience; Pyxis Oncology
  • Class Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Wet age-related macular degeneration

Most Recent Events

  • 29 Jun 2026 Efficacy and adverse events data from a phase II/III trial in Wet age-related macular degeneration (nAMD) released by Mabwell Bioscience
  • 04 Jun 2026 Efficacy data from a phase II/III trial in Wet age-related macular degeneration (nAMD) released by Mabwell Bioscience
  • 23 Aug 2023 Apexigen has been acquired and merged into Pyxis Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top